In keeping with our continuing efforts to support transparency and share input submissions for public policy consultations, PDCI is hosting responses to a recent CADTH survey that was conducted on behalf of the Provincial/Territorial (P/T) Expensive Drugs for Rare Disease Working Group (EDRD WG). The EDRD WG sought public feedback and ideas on its “proposal for a supplemental process for complex/specialized drugs that builds upon the existing national and jurisdictional drug review processes.” (source: EDRD WG Consultation Paper)

Consultations on a Supplemental Process for complex/specialty drugs occurred throughout the fall of 2018. Potential implementation of a revised process for health technology assessment, negotiations and possible mechanisms for reimbursement could be launched by P/Ts as early as Spring 2019, according to their consultation document.

If your organization submitted and retained copies of responses to the recent CADTH SurveyMonkey®, you are invited to share the response for public information through our PDCI sharing site. In keeping with PDCI’s efforts to share input submissions for ongoing public consultations, PDCI will add your response to the sharing page.

Please email your submission to drdresponses@pdci.ca if you would like your voice added to this page.

Visit PDCI’s Sharing Responses to Public Consultations to review other recent important stakeholder input on National Pharmacare and PMPRB price guideline reform.